{"id":9806,"date":"2012-06-06T18:26:13","date_gmt":"2012-06-06T22:26:13","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=9806"},"modified":"2012-06-06T18:26:13","modified_gmt":"2012-06-06T22:26:13","slug":"ivf-assessment-company-lands-18m-in-venture-capital","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=9806","title":{"rendered":"IVF Assessment Company Lands $18M in Venture Capital"},"content":{"rendered":"
\"Pregnancy<\/a>
(U.S. Centers for Disease Control)<\/figcaption><\/figure>\n

Auxogyn Inc.<\/a>, in Menlo Park, California, a developer of viability tests of embryos during in vitro fertilization<\/em> (IVF) procedures, has raised $18 million in series B venture funds, the second round of financing after initial start-up. The financing was led by new investor SR One — the corporate venture capital arm of GlaxoSmithKline — and includes all of the company’s series A investors: Kleiner Perkins Caufield and Byers, TPG Biotech, and Merck Serono Ventures.<\/p>\n

Proceeds from the round are expected to support regulatory clearance and commercial launch of Auxogyn’s Early Embryo Viability Assessment (Eeva), a non-invasive test that provides objective information about the viability of embryos during in vitro<\/em> fertilization. The Eeva test is designed to improve IVF outcomes by providing clinicians and patients with data to help them more confidently select embryos for transfer.<\/p>\n

Auxogyn says Eeva’s software automatically analyzes embryo development against scientifically and clinically validated cell-division timing metrics. The quantitative data on each embryo\u2019s development potential makes it possible for IVF clinics to optimize the treatment path for their patients undergoing IVF procedures.<\/p>\n

Eeva, says the company, is used with traditional embryo assessment techniques to offer IVF clinics and patients the potential to to reduce multiple births by enabling single embryo transfers for a large number of patients. The test is designed to fit into most standard IVF incubators and routine lab workflow.<\/p>\n

Lissa Goldenstein, president of Auxogyn, says the company plans to secure a CE Mark for Eeva and introduce the test commercially in Europe in the second half of 2012. The CE Mark<\/a> is required for many new products in Europe, and indicates the product meets EU safety, health and environmental protection requirements.<\/p>\n

Read more:<\/p>\n